RenovoRx, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
RNXT Nasdaq 2836 renovorx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for RenovoRx, Inc.

RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer - Oct 1st, 2026 6:30 am
RenovoRx H.C. Wainwright Presentation to Highlight RenovoCath Growth and Phase III TIGeR-PaC Timeline - Sep 2nd, 2026 8:39 am
RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th - Sep 2nd, 2026 6:30 am
RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer - Aug 25th, 2026 6:30 am
RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement - Aug 21st, 2026 6:30 am
RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment - Aug 20th, 2026 6:30 am
RenovoRx Eyes 2027 TIGeR-PaC Readout as RenovoCath Expands to 21 Centers - Aug 16th, 2026 7:01 pm
RenovoRx Inc (RNXT) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic Expansion ... - Aug 12th, 2026 11:02 pm
RenovoRx, Inc. Q2 2026 Earnings Call Summary - Aug 12th, 2026 8:15 pm
RenovoRx Q2 Earnings Call Highlights - Aug 12th, 2026 8:04 pm
RenovoRx, Inc. (RNXT) Reports Q2 Loss, Beats Revenue Estimates - Aug 12th, 2026 4:15 pm
RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth - Aug 12th, 2026 2:05 pm
RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer - Aug 11th, 2026 6:30 am
EXCLUSIVE: Renovorx Advances Its Targeted Pancreatic Cancer Therapy, Pivotal Data Expected in 2027 - Aug 11th, 2026 6:01 am
RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors - Aug 6th, 2026 6:30 am
RenovoRx to Highlight TAMP™ Platform at JonesTrading Virtual Key Opinion Leader Webinar on the Evolving Pancreatic Cancer Landscape, August 13th - Aug 4th, 2026 6:30 am
Krystal Biotech, Inc. (KRYS) Q2 Earnings and Revenues Beat Estimates - Aug 3rd, 2026 6:10 am
RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET - Jul 29th, 2026 6:30 am
iAccess Alpha Virtual Best Ideas Summer Investment Conference Begins Today - Jun 23rd, 2026 6:15 am